DESCRIPTION:  The decision to introduce a new vaccination program in a country is a process in which multiple decision makers participate. Each decision maker considers the value of the new vaccination program from different perspectives and is, therefore, interested in different measures of economic value. These measures include value for money and net present value and can be considered to be part of a complete assessment of economic value. The ISPOR Task Force on the Economic Evaluation of Vaccines for Infectious Diseases has selected three methods currently being used to assess the value of new vaccination programs (cost-effectiveness analysis, partial optimization modelling, and fiscal modelling). At this Forum, we will present an initial set of guidelines (perspective, comparator, time horizon, discounting, model structure, data requirement, outcome measures, uncertainty evaluation, transparency, and validation) for each of these methods as well as an exploration of how they can be extended beyond a focus on individual health outcomes to include a broader set of outcomes for the individual, household and the community. We will ask Forum participants to give the Task Force feedback on the initial guidelines for the traditional and extended value assessments.